On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...

Please provide your email address to receive an email when new articles are posted on . Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...

However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...